4-Methylmorpholine → HCID 86755342, compound

HRID 1005380Notes

Reaction equation

HRID 1005380 reaction equation
[C:1]([O:5][C:6]([N:8]1[C:12]2[CH2:13][C@H:14]([C:30](O)=[O:31])[CH:15]([C:23]([O:25][C:26]([CH3:29])([CH3:28])[CH3:27])=[O:24])[N:16]([C:17]3[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=3)[C:11]=2[N:10]=[CH:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[C:33]([N:35]([CH2:43][C:44]1[CH:49]=[CH:48][CH:47]=[CH:46][CH:45]=1)[CH2:36][CH2:37][C:38]1[N:42]=CNC=1)#[N:34].C1C=CC2N(O)N=[N:56][C:54]=2C=1.[CH3:60]N1CCOCC1>CN(C=O)C.C(Cl)CCl>[C:1]([O:5][C:6]([N:8]1[C:12]2[CH2:13][C@H:14]([C:30](=[O:31])[NH:42][CH2:38][CH2:37][C:36]3[N:35]([CH2:43][C:44]4[CH:45]=[CH:46][C:47]([C:54]#[N:56])=[CH:48][CH:49]=4)[CH:33]=[N:34][CH:60]=3)[CH:15]([C:23]([O:25][C:26]([CH3:29])([CH3:27])[CH3:28])=[O:24])[N:16]([C:17]3[CH:22]=[CH:21][CH:20]=[CH:19][CH:18]=3)[C:11]=2[N:10]=[CH:9]1)=[O:7])([CH3:3])([CH3:4])[CH3:2]

Participants

7

Procedure

To a solution of the product as described in Step A above, [4-phenyl-6,7-dihydro-4-H-imidazo[4,5]pyridine-1,5,6(S)-tricarboxylic acid 1,5-di-tert-butyl ester] (0.34 g, 0.826 mm), cyanobenzyl histamine (5)(0.187 g, 0.826 mm), HOBt (0.126 g, 0.826 mm), EDC (0.158 g, 0.826 mm) in DMF (5 ml) was added NMM (0.27 ml, 2.48 mm). The solvents were removed in vacuo and the residue was partitioned with EtOAc and saturated sodium bicarbonate. The EtOAc layer was dried with brine and magnesium sulfate. The EtOAc was removed in vacuo to obtain the title compound as a solid which was used in the next step as is.

Workup

  1. customThe solvents were removed in vacuo
  2. customthe residue was partitioned with EtOAc and saturated sodium bicarbonate
  3. dry with materialThe EtOAc layer was dried with brine and magnesium sulfate
  4. customThe EtOAc was removed in vacuo

Sources & evidence

ORD record
ord-999c44ef9f2f44ac86069c4bff7af531
Source dataset
uspto-grants-2000_04
Patent number
US06054466

Reaction notes

Loading…